Relugolix not checked
Sumitomo Pharma America, Inc. · TAK-385 · MVT-601
FollowEvery change as it happens, and a Monday email
Trials
5 active
8 in total · 4 in the EU
What this is
- How it works
- Gonadotropin Releasing Hormone Receptor Antagonist FDA class
- How it’s given
- “A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.”In the company’s words, NCT05862272 on ClinicalTrials.gov
- Tested for
- Uterine Fibroids, Endometriosis
- Main trialPhase 3
- “The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.”In the company’s words, NCT05862272 on ClinicalTrials.gov
- Other names
- ORGOVYX · TAK-385 · MVT-601 · RVT-601 · T-1331285 · MVT-601A · MYFEMBREE
Other drugs for Uterine Fibroids
Coming up1
- Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2029 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | |
| Phase 3Completed | 31 Dec 2024 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | |
| Phase 3Completed | 25 Feb 2025 | Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy | |
| Phase 1Completed | 28 May 2024 | Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | |
| Phase 3Authorised | not given | Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial. | |
| Phase 3Authorised | not given | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) | |
| Phase 2Authorised | not given | Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO) | |
| Phase 2Authorised | not given | REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026